Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

BACKGROUND: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. METHODS: This is a retrospective analysis of the phase 3 CAIRO3 study. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurk, Sophie A., Peeters, Petra H. M., Dorresteijn, Bram, de Jong, Pim A., Jourdan, Marion, Creemers, Geert‐Jan M., Erdkamp, Frans L. G., de Jongh, Felix E., Kint, Peter A. M., Poppema, Boelo J., Radema, Sandra A., Simkens, Lieke H. J., Tanis, Bea C., Tjin‐A‐Ton, Manuel L. R., Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, May, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997070/
https://www.ncbi.nlm.nih.gov/pubmed/31850687
http://dx.doi.org/10.1002/cam4.2787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997070/
https://www.ncbi.nlm.nih.gov/pubmed/31850687
http://dx.doi.org/10.1002/cam4.2787

Ejemplares similares